Design and development of a non-invasive controlled release sol-gel based- dual drug delivery system for simultaneous alleviation of intraocular pressure and retinal ganglionic cells degeneration in glaucoma
Implementing Organization
National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad
Principal Investigator
Dr. Dadi A srinivasarao
National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad
About
Glaucoma is a complex pathological condition characterized by increased resistance to aqueous humor drainage, leading to elevated intraocular pressure (IOP) and retinal ganglion cell (RGC) degeneration. It is the leading cause of irreversible blindness globally and in India. Current treatment strategies include lifelong administration of eye drops containing prostaglandins, β-blockers, or surgical methods like trabeculectomy. However, these methods do not improve the condition of RGC degeneration. The chronic nature of glaucoma demands frequent drug administrations, leading to poor patient compliance and treatment failure. sustained-release ocular implants or microparticles have been explored to prolong drug release in ocular tissues, but these require invasive surgical procedures or injections that can lead to severe ocular complications. A non-invasive (topical) route of administration holds an advantage over other routes. The complex anatomical and physiological barriers of the eye cause hindrance to drug permeation and retention, resulting in low bioavailability and sub-therapeutic levels of topically administered drugs. To develop a non-invasive sustained release dual drug delivery system, a multi-stimuli responsive, sustained release sol-gel based system is proposed. The system, in the liquid state at 25ᵒC, can transform into a gel upon topical eye drop administration. If successful, this system can be used as a platform technology for the topical administration of multiple therapeutic agents in the treatment of various ocular diseases, and the proposed combinatorial therapy can be translated to the clinic.
Source
Source
Anusandhan National Research Foundation/science and Engineering Research Board (sERB), DsT 2023-24
Science and Engineering Research Board (SERB), New Delhi
Anusandhan National Research Foundation (ANRF)
Quick Information
Area of Research
Life Sciences & Biotechnology
Start Year
2024
End Year
2026
Sanction Amount
₹ 29.40 L
Status
Ongoing
Contact
srinivasarao.ananda@niperhyd.ac.in
Output
No. of Research Paper
00
Technologies (If Any)
00
No. of PhD Produced
00
No. of Patents
Filed :00
Grant :00
Disclaimer:
Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.
Please enter your details
Please provide your name and email to continue. Your details are saved in this browser for future use.
Latest Updates
Loading…
⚠️
You are leaving this website
You are about to be redirected to an external website that is not operated by
India Science, Technology & Innovation (ISTI) Portal.